Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study
- 1 May 2017
- journal article
- research article
- Published by Elsevier in The Lancet Haematology
- Vol. 4 (5) , e237-e244
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- 30-Year Mortality After Venous ThromboembolismCirculation, 2014
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2013
- Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysisBMJ, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Antithrombotic Therapy for VTE DiseaseChest, 2012
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Preventing pulmonary embolism and deep vein thrombosis: a ‘call to action’ for vascular medicine specialistsJournal of Thrombosis and Haemostasis, 2007
- The Long-Term Clinical Course of Acute Deep Venous ThrombosisAnnals of Internal Medicine, 1996